NZ776807A - Antibody that binds to vegf and il-1beta and methods of use - Google Patents
Antibody that binds to vegf and il-1beta and methods of useInfo
- Publication number
- NZ776807A NZ776807A NZ776807A NZ77680719A NZ776807A NZ 776807 A NZ776807 A NZ 776807A NZ 776807 A NZ776807 A NZ 776807A NZ 77680719 A NZ77680719 A NZ 77680719A NZ 776807 A NZ776807 A NZ 776807A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- 1beta
- cdr
- human
- vegf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
Claims (16)
1. An antibody that binds to human VEGF and to human IL-1beta, comprising a 5 VH sequence of SEQ ID NO:11 and a VL sequence of SEQ ID NO:12.
2. The antibody of claim 1, wherein the antibody comprises a VEGF paratope and an IL-1beta paratope within one cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the 10 VEGF paratope comprises amino acid residues from CDR-H2, CDR-L1 and CDR-L3 of the antibody, and wherein the IL-1beta paratope comprises amino acid residues from the CDR-H1, CDR-H3 and CDR-L2 of the antibody.
3. The antibody of any one of the preceding claims comprising a heavy chain amino 15 acid sequence of SEQ ID NO:20 and a light chain amino acid sequence of SEQ ID NO:19.
4. The antibody of any one of the preceding claims, wherein an antibody Fab fragment of the antibody binds (i) to human VEGF121 with a K of less than 10 20 pM as measured by surface plasmon resonance, and (ii) to human IL-1beta with a K of less than 30 pM as measured by surface plasmon resonance.
5. The antibody of any one of the preceding claims, wherein an antibody Fab fragment of the antibody exhibits an aggregation onset temperature of more than 25 70 °C.
6. The antibody of any one of the preceding claims, wherein an antibody Fab fragment of the antibody exhibits a melting temperature of more than 80 °C as measured by dynamic light scattering.
7. The antibody of any one of the preceding claims, wherein the antibody is a bispecific antibody or binding fragment thereof.
8. An isolated nucleic acid encoding the antibody of any one of claims 1 to 7.
9. An isolated host cell comprising the nucleic acid of claim 8.
10. An expression vector comprising the nucleic acid of claim 8.
11. A method of producing an antibody that binds to human VEGF and to human IL- 1beta comprising culturing the host cell of claim 9 so that the antibody is produced.
12. The antibody of any one of claims 1-7 substantially as herein described and with reference to any example thereof and with or without reference to the figures. 10
13. The nucleic acid of claim 8 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
14. The host cell of claim 9 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
15. The vector of claim 10 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
16. The method of claim 11 substantially as herein described and with reference to 20 any example thereof and with or without reference to the figures. 1 / 12
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215023 | 2018-12-21 | ||
| PCT/EP2019/086529 WO2020127873A1 (en) | 2018-12-21 | 2019-12-20 | Antibody that binds to vegf and il-1beta and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ776807A true NZ776807A (en) | 2025-05-02 |
| NZ776807B2 NZ776807B2 (en) | 2025-08-05 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520657A5 (en) | ||
| JP2020536543A5 (en) | ||
| HRP20190932T1 (en) | Antibody molecules which bind il-17a and il-17f | |
| US20220403028A1 (en) | Novel anti-cd3 antibodies | |
| AR126758A2 (en) | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | |
| JP2012525829A5 (en) | ||
| PE20121646A1 (en) | ANTI-TSLP ANTIBODY MODIFIED BY GENETIC ENGINEERING TECHNIQUES | |
| HRP20191697T1 (en) | Binding molecules for bcma and cd3 | |
| GB2595379A (en) | Anti-BTLA antibodies | |
| RU2012147286A (en) | HUMANIZED ANTIBODIES TO FACTOR D AND THEIR APPLICATIONS | |
| FI3322727T3 (en) | Humanized or chimeric CD3 antibodies | |
| JP2017505125A5 (en) | ||
| CR20240482A (en) | Anti-tl1a antibodies and methods of use thereof | |
| JP2022514734A5 (en) | ||
| WO2022157773A2 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP2020532572A5 (en) | ||
| JP2023549555A5 (en) | ||
| AU2019263850A1 (en) | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom | |
| AR126009A1 (en) | CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM | |
| JP2022501065A5 (en) | ||
| FI4031569T3 (en) | STEM CELL FACTOR ANTIBODIES AND METHODS OF USING THEM | |
| JP2022523145A5 (en) | ||
| PE20212269A1 (en) | ANTI-TREM1 ANTIBODIES AND RELATED METHODS | |
| JP7652705B2 (en) | Antibodies with specificity for BTN2 and uses thereof | |
| NZ776807B2 (en) | Antibody that binds to vegf and il-1beta and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |